India globalization capital, inc. opens marketing and research hub in colombia

India globalization capital, inc. announced that it has opened a marketing and research office in colombia, south america. hamsa biochem sas, a new beneficially owned subsidiary of igc, will focus on marketing and research initiatives to advance hyalolex, holi hemp, and other products in latin america and among the greater hispanic community in the united states, in compliance with applicable law and regulations. hyalolex, which is currently available in more than 40 dispensaries in puerto rico, is based on a formulation described in a patent filing acquired from the university of south florida (usf) in 2017, with pre-clinical research that indicates that micro-doses of cannabis, in combination with other natural compounds, may be beneficial to alzheimer’s cell lines and to memory in transgenic mice. hamsa biochem will focus on three goals – (1) expanding the distribution of the company’s products into latin america, (2) securing a low cost-basis for procuring raw materials like cbd (cannabidiol) and hemp extracts, and (3) advancing the company’s research platform for uses including medical trials and advanced natural product chemistry.
IGC Ratings Summary
IGC Quant Ranking